Open-Label, Randomized, 6-Way Crossover, Single-Dose Study to Determine the Pharmacokinetics of Batefenterol (GSK961081) and Fluticasone Furoate When Administered Alone or in Combination-Reference-Cited by-同舟云学术

Open-Label, Randomized, 6-Way Crossover, Single-Dose Study to Determine the Pharmacokinetics of Batefenterol (GSK961081) and Fluticasone Furoate When Administered Alone or in Combination

Published:2016-06-26 Issue:5 Volume:5 Page:399-407
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Ambery Claire¹,Riddell Kylie²,Daley-Yates Peter³

Affiliation:

1. Quantitative Sciences Division, GSK; Stockley Park West; Uxbridge Middlesex UK

2. GSK; Ermington NSW Australia

3. Clinical Pharmacology; GSK, Research and Development; Uxbridge Middlesex UK

Funder

GSK

ClinicalTrials.gov identifier

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Reference26 articles.

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015 http://www.goldcopd.org

2. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper;Celli;Eur Respir J,2004

3. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients;Cazzola;Respir Med,2005

4. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD;Cazzola;Pulm Pharmacol Ther,2010

5. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease;Welte;Am J Respir Crit Care Med,2009

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of core therapeutic targets for Monkeypox virus and repurposing potential of drugs against them: An in silico approach;Computers in Biology and Medicine;2023-07

2. Bronchodilators for Airway Disease;Encyclopedia of Respiratory Medicine;2022

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease

;Journal of Experimental Pharmacology;2020-12

4. A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD;BMC Pulmonary Medicine;2020-05-04

5. Pharmacokinetics, Excretion, and Mass Balance of [14 C]-Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men;Clinical Pharmacology in Drug Development;2018-09-19